Published

Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Journal of psychoactive drugs
Date: 2017-01-01
Source: PubMed
DOI: 10.1080/02791072.2017.1320734
PubMed: 28481178

Authors

Thomas K Malcolm B Lastra D

Watch author

Derived topics and classifications

psilocybin Depression Anxiety Addiction Receptor Pharmacology Default Mode Network Clinical Trial Review Article Safety Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 3 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Therapeutic Potential of Psilocybin in Psychiatric Disorders: Mechanisms, Efficacy, and Clinical Implications2026-04-01 Acute psilocin increased cortical activity in rat2026-02-04 Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders.2017-01-01

Related papers

Harnessing neuroplasticity with psychoplastogens: the essential role of psychotherapy in psychedelic treatment optimizationFrontiers in Psychiatry · 2025-04-08 Psilocybin therapy: A novel approach to treating depressionInternational Journal of Surgery Global Health · 2023-06-02 Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial.Trials · 2024-05-21 Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness (PDR-Study)ClinicalTrials.gov · 2025-05-28 Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial.Contemporary clinical trials · 2022-12-01 S1 Appendix - Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trialFigshare · 2025-09-19 A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10 A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10